Unknown

Dataset Information

0

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).


ABSTRACT:

Background

Non-small-cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations may exhibit primary resistance to EGFR tyrosine kinase inhibitor (TKI). We aimed to examine genomic alterations associated with de novo resistance to gefitinib in a prospective study of NSCLC patients.

Patients and methods

One-hundred and fifty two patients with activating EGFR mutations were included in this study and 136 patients' tumor sample were available for targeted sequencing of genomic alterations in 22 genes using the Colon and Lung Cancer panel (Ampliseq, Life Technologies).

Results

All 132 patients with EGFR mutation were treated with gefitinib for their treatment of advanced NSCLC. Twenty patients showed primary resistance to EGFR TKI, and were classified as non-responders. A total of 543 somatic single-nucleotide variants (498 missense, 13 nonsense) and 32 frameshift insertions/deletions, with a median of 3 mutations per sample. TP53 was most commonly mutated (47%) and mutations in SMAD4 was also common (19%), as well as DDR2 (16%), PIK3CA (15%), STK11 (14%), and BRAF (7%). Genomic mutations in the PI3K/Akt/mTOR pathway were commonly found in non-responders (45%) compared to responders (27%), and they had significantly shorter progression-free survival and overall survival compared to patients without mutations (2.1 vs. 12.8 months, P=0.04, 15.7 vs. not reached, P<0.001). FGFR 1-3 alterations, KRAS mutations and TP53 mutations were more commonly detected in non-responders compared to responders.

Conclusions

Genomic mutations in the PI3K/Akt/mTOR pathway were commonly identified in non-responders and may confer resistance to EGFR TKI. Screening lung adenocarcinoma patients with clinical cancer gene test may aid in selecting out those who show primary resistance to EGFR TKI (NCT01697163).

SUBMITTER: Lim SM 

PROVIDER: S-EPMC5095002 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).

Lim Sun Min SM   Kim Hye Ryun HR   Cho Eun Kyung EK   Min Young Joo YJ   Ahn Jin Seok JS   Ahn Myung-Ju MJ   Park Keunchil K   Cho Byoung Chul BC   Lee Ji-Hyun JH   Jeong Hye Cheol HC   Kim Eun Kyung EK   Kim Joo-Hang JH  

Oncotarget 20160601 24


<h4>Background</h4>Non-small-cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations may exhibit primary resistance to EGFR tyrosine kinase inhibitor (TKI). We aimed to examine genomic alterations associated with de novo resistance to gefitinib in a prospective study of NSCLC patients.<h4>Patients and methods</h4>One-hundred and fifty two patients with activating EGFR mutations were included in this study and 136 patients' tumor sample were available f  ...[more]

Similar Datasets

| S-EPMC4886131 | biostudies-literature
| S-EPMC8797694 | biostudies-literature
| S-EPMC2817631 | biostudies-literature
| S-EPMC2642732 | biostudies-literature
| S-EPMC6604188 | biostudies-literature
| S-EPMC2043012 | biostudies-literature
| PRJNA352077 | ENA
| S-EPMC4129521 | biostudies-literature
| S-EPMC9317954 | biostudies-literature
2016-11-02 | GSE89411 | GEO